专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US08106076B2 Crystalline S-omeprazole strontium hydrate, method for preparing same, and pharmaceutical composition containing same 有权
标题翻译：结晶S-奥美拉唑锶水合物，其制备方法和含有它们的药物组合物
公开(公告)号：US08106076B2
公开(公告)日：2012-01-31
申请号：US12425499
申请日：2009-04-17
申请人： Tae Hee Ha , Hee Sook Oh , Won Jeoung Kim , Chang Hee Park , Eun Young Kim , Young Hoon Kim , Kwee Hyun Suh , Gwan Sun Lee
发明人： Tae Hee Ha , Hee Sook Oh , Won Jeoung Kim , Chang Hee Park , Eun Young Kim , Young Hoon Kim , Kwee Hyun Suh , Gwan Sun Lee
IPC分类号： A61K31/4439 , C07D401/12
CPC分类号： C07D401/12
摘要： This invention provides a crystalline S-omeprazole strontium hydrate for the prevention or treatment of gastric acid-related diseases, which has high optical purity, theremostability, solubility and nonhygroscopicity, a method for preparing same, and a pharmaceutical composition containing same.
摘要翻译：本发明提供了一种用于预防或治疗胃酸相关疾病的结晶性S-奥美拉唑水合锶，其具有高光学纯度，耐受性，溶解性和不吸湿性，其制备方法和含有该组合物的药物组合物。

2. 发明授权

US08513426B2 Crystalline S-omeprazole strontium hydrate, method for preparing same, and pharmaceutical composition containing same 有权
公开(公告)号：US08513426B2
公开(公告)日：2013-08-20
申请号：US12914032
申请日：2010-10-28
申请人： Tae Hee Ha , Hee Sook Oh , Won Jeoung Kim , Chang Hee Park , Eun Young Kim , Young Hoon Kim , Kwee Hyun Suh , Gwan Sun Lee
发明人： Tae Hee Ha , Hee Sook Oh , Won Jeoung Kim , Chang Hee Park , Eun Young Kim , Young Hoon Kim , Kwee Hyun Suh , Gwan Sun Lee
IPC分类号： C07D401/12
CPC分类号： C07D401/12
摘要： Disclosed are a crystalline S-omeprazole strontium hydrate for the prevention or treatment of gastric acid-related diseases, which has high optical purity, theremostability, solubility and nonhygroscopicity, a method for preparing same, and a pharmaceutical composition containing same.

3. 发明申请

US20110046383A1 CRYSTALLINE S-OMEPRAZOLE STRONTIUM HYDRATE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME 有权
标题翻译：水溶性S-奥美拉唑水合物，其制备方法和含有其的药物组合物
公开(公告)号：US20110046383A1
公开(公告)日：2011-02-24
申请号：US12914032
申请日：2010-10-28
申请人： Tae Hee HA , Hee Sook Oh , Won Jeoung Kim , Chang Hee Park , Eun Young Kim , Young Hoon Kim , Kwee Hyun Suh , Gwan Sun Lee
发明人： Tae Hee HA , Hee Sook Oh , Won Jeoung Kim , Chang Hee Park , Eun Young Kim , Young Hoon Kim , Kwee Hyun Suh , Gwan Sun Lee
IPC分类号： C07D401/12
CPC分类号： C07D401/12
摘要： Disclosed are a crystalline S-omeprazole strontium hydrate for the prevention or treatment of gastric acid-related diseases, which has high optical purity, theremostability, solubility and nonhygroscopicity, a method for preparing same, and a pharmaceutical composition containing same.
摘要翻译：公开了一种用于预防或治疗胃酸相关疾病的结晶性S-奥美拉唑锶水合物，其具有高光学纯度，耐久性，溶解性和不吸湿性，其制备方法和含有其的药物组合物。

4. 发明授权

US07576219B2 Crystalline S-omeprazole strontium hydrate, method for preparing same, and pharmaceutical composition containing same 有权
标题翻译：结晶S-奥美拉唑锶水合物，其制备方法和含有它们的药物组合物
公开(公告)号：US07576219B2
公开(公告)日：2009-08-18
申请号：US11374034
申请日：2006-03-14
申请人： Tae Hee Ha , Hee Sook Oh , Won Jeoung Kim , Chang Hee Park , Eun Young Kim , Young Hoon Kim , Kwee Hyun Suh , Gwan Sun Lee
发明人： Tae Hee Ha , Hee Sook Oh , Won Jeoung Kim , Chang Hee Park , Eun Young Kim , Young Hoon Kim , Kwee Hyun Suh , Gwan Sun Lee
IPC分类号： C07D401/12
CPC分类号： C07D401/12
摘要： This invention provides a crystalline S-omeprazole strontium hydrate for the prevention or treatment of gastric acid-related diseases, which has high optical purity, theremostability, solubility and nonhygroscopicity, a method for preparing same, and a pharmaceutical composition containing same.
摘要翻译：本发明提供了一种用于预防或治疗胃酸相关疾病的结晶性S-奥美拉唑水合锶，其具有高光学纯度，耐受性，溶解性和不吸湿性，其制备方法和含有该组合物的药物组合物。

5. 发明申请

US20100137367A1 NOVEL CRYSTALLINE BEPOTASTINE METAL SALT HYDRATE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME 审中-公开
标题翻译：新型水晶金属盐水合物，其制备方法和包含其的药物组合物
公开(公告)号：US20100137367A1
公开(公告)日：2010-06-03
申请号：US12531003
申请日：2008-04-04
申请人： Tae Hee Ha , Chang Hee Park , Won Jeoung Kim , Hee Sook Oh , Seung Hwan Cho , Cheol Kyung Kim , Kwee Hyun Suh , Gwan Sun Lee
发明人： Tae Hee Ha , Chang Hee Park , Won Jeoung Kim , Hee Sook Oh , Seung Hwan Cho , Cheol Kyung Kim , Kwee Hyun Suh , Gwan Sun Lee
IPC分类号： A61K31/4545 , C07D401/12 , A61P17/00
CPC分类号： C07D401/12 , A61K9/143
摘要： The present invention discloses a non-hygroscopic crystalline bepotastine metal salt hydrate, a method for preparing same, and a pharmaceutical composition comprising same for treating or preventing a histamine-mediated disease or an allergic disease.
摘要翻译：本发明公开了一种非吸湿结晶贝卡斯汀金属盐水合物及其制备方法，以及包含其的药物组合物，用于治疗或预防组胺介导的疾病或过敏性疾病。

6. 发明申请

US20100168433A1 PROCESS FOR PREPARING BEPOTASTINE AND INTERMEDIATES USED THEREIN 审中-公开
标题翻译：用于制备BEPOTASTINE及其中间体的方法
公开(公告)号：US20100168433A1
公开(公告)日：2010-07-01
申请号：US12663983
申请日：2008-06-05
申请人： Tae Hee Ha , Chang Hee Park , Won Jeoung Kim , Soohwa Cho , Han Kyong Kim , Kwee Hyun Suh
发明人： Tae Hee Ha , Chang Hee Park , Won Jeoung Kim , Soohwa Cho , Han Kyong Kim , Kwee Hyun Suh
IPC分类号： C07D401/12
CPC分类号： C07D401/12
摘要： A process for stereospecific preparation of bepotastine of formula (I) and novel intermediates used therein having formulae (II) to (IV) are provided. The inventive process comprises subjecting (RS)-4-[(4-chlorophenyl)(2-pyridyl)methoxy]piperidine to a reaction with a 4-halobutanoic acid l-menthyl ester, halo being chloro, bromo or iodo, in an organic solvent in the presence of a base to produce (RS)-bepotastine l-menthyl ester of formula (II), conducting a reaction of the compound of formula (II) with N-benzyloxycarbonyl L-aspartic acid in an organic solvent to induce selective precipitation of bepotastine l-menthyl ester.N-benzyloxycarbonyl L-aspartate of formula (III), filtering the precipitates formed in step 2) to isolate the compound of formula (III), treating the compound of formula (III) with a base to liberate bepotastine l-menthyl ester of formula (IV), and hydrolyzing the compound of formula (IV) in the presence of a base. The inventive process can provide bepotastine having a high optical purity of not less than 99.5% in a high yield, and thus, is useful in the development of anti-histamines and anti-allergic agents.
摘要翻译：提供了式（I）的贝他辛汀的立体特异性制备方法和其中使用的具有式（II）至（IV）的新型中间体。本发明的方法包括使（RS）-4 - [（4-氯苯基）（2-吡啶基）甲氧基]哌啶与4-卤代丁酸1-薄荷酯，卤素为氯，溴或碘的有机反应溶剂在碱的存在下反应以制备式（II）的（RS） - 贝斯塔司汀l-薄荷酯，在有机溶剂中进行式（II）化合物与N-苄氧基羰基L-天冬氨酸的反应，以诱导选择性贝他辛汀1-薄荷酯的沉淀。式（III）的N-苄氧基羰基L-天冬氨酸盐，过滤步骤2）中形成的沉淀物以分离式（III）化合物，用碱将式（III）化合物释放式（IV）的布他辛酯l-薄荷酯，并在碱的存在下水解式（IV）的化合物。本发明方法可以以高产率提供具有不低于99.5％的高光学纯度的贝他斯汀，因此可用于抗组胺和抗过敏剂的开发。

7. 发明申请

US20090209576A1 PHARMACEUTICAL COMPOSITION CONTAINING CLOPIDOGREL CAMPHORSULFONATE OR POLYMORPHIC FORMS THEREOF 审中-公开
标题翻译：含有角叉菜酮或其多形态的药物组合物
公开(公告)号：US20090209576A1
公开(公告)日：2009-08-20
申请号：US12293357
申请日：2007-03-15
申请人： Won Jeoung Kim , Han Kyong Kim , Kwee Hyun Suh , Gwan Sun Lee
发明人： Won Jeoung Kim , Han Kyong Kim , Kwee Hyun Suh , Gwan Sun Lee
IPC分类号： A61K31/4365 , C07D495/04 , A61P7/00
CPC分类号： A61K31/47
摘要： A pharmaceutical composition of the present invention which comprises clopidogrel camphorsulfonate of formula (I) or its polymorphic forms as an active ingredient is useful for treating or preventing a platelet aggregation-associated disease.
摘要翻译：包含式（I）的氯吡格雷樟脑磺酸盐或其多晶型物质作为活性成分的本发明的药物组合物可用于治疗或预防血小板聚集相关疾病。

8. 发明申请

US20140163226A1 NOVEL PYRIMIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION INCLUDING SAME AS AN ACTIVE INGREDIENT 审中-公开
标题翻译：新型吡咯烷衍生物和药物组合物，包括作为活性成分的组合物
公开(公告)号：US20140163226A1
公开(公告)日：2014-06-12
申请号：US14232667
申请日：2012-06-29
申请人： Chul Hyun Park , Won Jeoung Kim , Young Hee Jung , Nam Du Kim , Young Kil Chang , Maeng Sup Kim
发明人： Chul Hyun Park , Won Jeoung Kim , Young Hee Jung , Nam Du Kim , Young Kil Chang , Maeng Sup Kim
IPC分类号： C07D495/04 , C07D487/04
CPC分类号： C07D495/04 , C07D487/04
摘要： The present invention relates to a compound represented by formula (I) for inhibiting the activity of diacylglycerol O-acyltransferase type 1 (DGAT1), and pharmaceutically acceptable salts thereof, and a pharmaceutical composition comprising same as an active ingredient. The compound of the present invention may be used effectively in the treatment or prevention of a disease or condition mediated by the activity of DGAT1 such as obesity, type II diabetes, dyslipidemia, metabolic syndrome, and the like, without any adverse effects: wherein A, B, X, and R5 to R7 are the same as defined in the specification.
摘要翻译：本发明涉及一种抑制二酰基甘油O-酰基转移酶1型（DGAT1）的活性的式（I）表示的化合物及其药学上可接受的盐，以及含有该活性成分的药物组合物。本发明的化合物可以有效地用于治疗或预防由诸如肥胖，II型糖尿病，血脂异常，代谢综合征等的DGAT1的活性介导的疾病或病症，而没有任何不利影响：其中A ，B，X和R5至R7与说明书中所定义相同。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式